Self-delivery photothermal-boosted-nanobike multi-overcoming immune escape by photothermal/chemical/immune synergistic therapy against HCC

Huizhen Yang,Weiwei Mu,Shijun Yuan,Han Yang,Lili Chang,Xiao Sang,Tong Gao,Shuang Liang,Xiaoqing Liu,Shunli Fu,Zipeng Zhang,Yongjun Liu,Na Zhang

DOI: https://doi.org/10.1186/s12951-024-02399-3

IF: 10.2

2024-03-31

Journal of Nanobiotechnology

Abstract:Immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy have shown encouraging clinical benefits for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC). Nevertheless, therapeutic efficacy and wide clinical applicability remain a challenge due to "cold" tumors' immunological characteristics. Tumor immunosuppressive microenvironment (TIME) continuously natural force for immune escape by extracellular matrix (ECM) infiltration, tumor angiogenesis, and tumor cell proliferation. Herein, we proposed a novel concept by multi-overcoming immune escape to maximize the ICIs combined with antiangiogenic therapy efficacy against HCC. A self-delivery photothermal-boosted-NanoBike (BPSP) composed of black phosphorus (BP) tandem-augmented anti-PD-L1 mAb plus sorafenib (SF) is meticulously constructed as a triple combination therapy strategy. The simplicity of BPSP's composition, with no additional ingredients added, makes it easy to prepare and presents promising marketing opportunities. (1) NIR-II-activated BPSP performs photothermal therapy (PTT) and remodels ECM by depleting collagen I, promoting deep penetration of therapeutics and immune cells. (2) PTT promotes SF release and SF exerts anti-vascular effects and down-regulates PD-L1 via RAS/RAF/ERK pathway inhibition, enhancing the efficacy of anti-PD-L1 mAb in overcoming immune evasion. (3) Anti-PD-L1 mAb block PD1/PD-L1 recognition and PTT-induced ICD initiates effector T cells and increases response rates of PD-L1 mAb. Highly-encapsulated BPSP converted 'cold' tumors into 'hot' ones, improved CTL/Treg ratio, and cured orthotopic HCC tumors in mice. Thus, multi-overcoming immune escape offers new possibilities for advancing immunotherapies, and photothermal/chemical/immune synergistic therapy shows promise in the clinical development of HCC.

biotechnology & applied microbiology,nanoscience & nanotechnology

What problem does this paper attempt to address?

This paper aims to address key issues in the immunotherapy of hepatocellular carcinoma (HCC). Specifically, it proposes a novel strategy to enhance the efficacy of immune checkpoint inhibitors (ICIs) combined with anti-angiogenic therapy by overcoming immune evasion through multiple pathways. The core of the research lies in the use of self-delivering photothermal-enhanced nanocarriers (BPSP) for the treatment of HCC.

### Main Issues:
1. **Immune Evasion**: The tumor microenvironment (TIME) of HCC is complex and immunosuppressive, making "cold" tumors difficult to respond to immunotherapy.
2. **Limitations of Existing Therapies**: Although immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) have shown some clinical efficacy, the complex signaling interactions mean that single-target ICIs are insufficient to overcome immune evasion.
3. **Multiple Factors Leading to Immune Evasion**: Factors such as extracellular matrix (ECM) infiltration, tumor angiogenesis, and tumor cell proliferation collectively limit the effectiveness of immunotherapy.

### Solution:
- **Composition of BPSP**: BPSP consists of black phosphorus (BP) nanosheets, anti-PD-L1 monoclonal antibodies, and sorafenib (SF).
- **Triple Synergistic Effect**: BPSP achieves effective treatment of HCC through a triple combination strategy of photothermal therapy (PTT), chemotherapy (SF), and immunotherapy (anti-PD-L1 mAb).
- **Specific Mechanisms**:
- **Photothermal Therapy (PTT)**: BPSP performs PTT under near-infrared (NIR-II) activation, remodeling the ECM and promoting deep penetration of drugs and immune cells.
- **Chemotherapy (SF)**: SF downregulates PD-L1 expression by inhibiting the RAS/RAF/ERK pathway, enhancing the effect of anti-PD-L1 mAb in overcoming immune evasion.
- **Immunotherapy (anti-PD-L1 mAb)**: Anti-PD-L1 mAb blocks PD-1/PD-L1 recognition, and PTT-induced immunogenic cell death (ICD) further increases the response rate of PD-L1 mAb.

### Conclusion:
This study achieves the transformation of "cold" tumors into "hot" tumors through BPSP, improves the CTL/Treg ratio, and cures orthotopic HCC tumors in mice. Therefore, the strategy of overcoming immune evasion through multiple pathways provides new possibilities for the immunotherapy of HCC.